Vertex Pharmaceuticals (VRTX) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted an opinion ...
The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...
Verve Therapeutics remains a high-reward investment despite setbacks. Click here to find out why VERV stock is a Buy.
The encouraging result comes just days after the US FDA approved Vertex Pharma's non-opioid painkiller Journavx (suzetrigine), an oral NaV1.8 inhibitor, as a treatment for acute pain, representing ...